BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31578734)

  • 1. Diagnostic utility of pan-Trk immunohistochemistry for inflammatory myofibroblastic tumours.
    Yamamoto H; Nozaki Y; Kohashi K; Kinoshita I; Oda Y
    Histopathology; 2020 Apr; 76(5):774-778. PubMed ID: 31578734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
    Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
    Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors.
    Csanyi-Bastien M; Lanic MD; Beaussire L; Ferric S; François A; Meseure D; Jardin F; Wassef M; Ruminy P; Laé M
    Am J Surg Pathol; 2021 Nov; 45(11):1487-1498. PubMed ID: 33899788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary inflammatory myofibroblastic tumour of the liver: a clinicopathological and genetic study including a subset with ETV6::NTRK3 fusion.
    Han Q; Zhang Z; He X; Chen M; Pang X; Chen C; Du T; Zhang H
    Histopathology; 2023 May; 82(6):925-936. PubMed ID: 36748182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
    Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
    Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics.
    Hung YP; Fletcher CDM; Hornick JL
    Histopathology; 2018 Oct; 73(4):634-644. PubMed ID: 29863809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma.
    Hung YP; Jo VY; Hornick JL
    Histopathology; 2019 Jul; 75(1):54-62. PubMed ID: 30801752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors.
    Hornick JL; Sholl LM; Dal Cin P; Childress MA; Lovly CM
    Mod Pathol; 2015 May; 28(5):732-9. PubMed ID: 25612511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.
    Mariño-Enríquez A; Wang WL; Roy A; Lopez-Terrada D; Lazar AJ; Fletcher CD; Coffin CM; Hornick JL
    Am J Surg Pathol; 2011 Jan; 35(1):135-44. PubMed ID: 21164297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors.
    Alassiri AH; Ali RH; Shen Y; Lum A; Strahlendorf C; Deyell R; Rassekh R; Sorensen PH; Laskin J; Marra M; Yip S; Lee CH; Ng TL
    Am J Surg Pathol; 2016 Aug; 40(8):1051-61. PubMed ID: 27259007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using pan-TRK and RET Immunohistochemistry for the Detection of Fusion Types of Salivary Gland Secretory Carcinoma.
    Su YJ; Lee YH; Jin YT; Hsieh MS
    Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):264-272. PubMed ID: 35384876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
    Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
    Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.
    Chang JC; Zhang L; Drilon AE; Chi P; Alaggio R; Borsu L; Benayed R; Travis WD; Ladanyi M; Antonescu CR
    J Thorac Oncol; 2019 May; 14(5):825-834. PubMed ID: 30550870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
    Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
    Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion.
    Xu B; Haroon Al Rasheed MR; Antonescu CR; Alex D; Frosina D; Ghossein R; Jungbluth AA; Katabi N
    Histopathology; 2020 Feb; 76(3):375-382. PubMed ID: 31448442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-TRK Immunohistochemistry: A Useful Diagnostic Adjunct For Secretory Carcinoma of the Breast.
    Harrison BT; Fowler E; Krings G; Chen YY; Bean GR; Vincent-Salomon A; Fuhrmann L; Barnick SE; Chen B; Hosfield EM; Hornick JL; Schnitt SJ
    Am J Surg Pathol; 2019 Dec; 43(12):1693-1700. PubMed ID: 31498178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
    Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrum of kinase gene rearrangements in a large series of paediatric inflammatory myofibroblastic tumours.
    Preobrazhenskaya EV; Suleymanova AM; Bizin IV; Zagrebin FA; Romanko AA; Saitova ES; Mulkidzhan RS; Imyanitov EN
    Histopathology; 2023 Jul; 83(1):109-115. PubMed ID: 37071060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets.
    Vernemmen AIP; Samarska IV; Speel EM; Riedl RG; Goudkade D; de Bruïne AP; Wouda S; van Marion AM; Verlinden IV; van Lijnschoten I; Friederich P; Winnepenninckx VJL; Zur Hausen A; Sciot RME; van den Hout MFCM
    Histopathology; 2024 Apr; 84(5):794-809. PubMed ID: 38155480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases.
    Collins K; Ramalingam P; Euscher ED; Reques Llanos A; García A; Malpica A
    Am J Surg Pathol; 2022 Jan; 46(1):105-117. PubMed ID: 34138797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.